SCNI

Scinai Immunotherapeutics Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website cinai.com
Employees(FY) 33
ISIN US09073Q3039

Performance

+0.89%

+23.64%

-5.82%

-21.48%

-42.9%

YTD

-51.43%

Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Advanced Technical Analysis

Technical Analysis of SCNI 2024-12-20

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 43 and the Technical Score at 46 indicating a slight bearish bias, while the Oscillators Score at 50 suggests a balanced outlook. This combination implies that the stock is currently in a consolidation phase, lacking strong momentum in either direction.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SCNI

Stock Rank

Recent News & Updates

2024-12-15 20:25
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.(Prnewswire)
2024-12-04 19:25
Prof. Michael Schn, Director of Dermatology and Venereology at the University Medical Center Gttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board(Prnewswire)
2024-11-26 19:00
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board(Yahoo Finance)
2024-11-26 19:00
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology RandD at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board(Prnewswire)
2024-11-21 18:15
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million(Prnewswire)
2024-10-30 18:59
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024(Prnewswire)
2024-09-15 19:00
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies(Prnewswire)
2024-09-08 23:12
IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.(Globenewswire)
2024-08-28 18:31
Scinai Regains Full Compliance with Nasdaq Listing Requirements(Prnewswire)
2024-08-20 20:45
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000(Prnewswire)
2024-08-19 21:30
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder(Prnewswire)
2024-08-14 19:00
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23(Prnewswire)
2024-08-12 19:00
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity(Prnewswire)
2024-08-04 18:30
7 F-Rated Stocks for Your August 2024 Sell List(Investorplace)
2024-07-22 19:00
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb(Prnewswire)
2024-07-15 00:41
PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition(Investorplace)
2024-07-15 00:22
M Stock Plunges 13% as Macy's Calls Off Take-Private Talks(Investorplace)
2024-07-15 00:04
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?(Investorplace)
2024-07-14 19:00
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model(Prnewswire)
2024-07-07 20:14
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity(Prnewswire)
2024-07-02 21:32
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements(Prnewswire)
2024-07-02 01:52
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024(Investorplace)
2024-07-01 20:12
Scinai Publishes Q1 2024 Financial Results and Provides Business Update(Prnewswire)
2024-06-20 19:52
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-06-16 19:56
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?(Investorplace)
2024-06-16 19:40
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-06-12 19:00
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity(Prnewswire)
2024-06-06 19:00
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement(Prnewswire)
2024-06-02 22:52
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023(Investorplace)
2024-05-24 04:01
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.